How to get acquisition ready – a seller’s guide to merger and acquisition in pharma
pharmaphorum
DECEMBER 28, 2022
In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. These teams will include experts in regulatory, GMP compliance and quality systems, often including ex-FDA and MHRA inspectors and industry experts. It is also an ideal opportunity to simplify as well as harmonise.
106 
Let's personalize your content